Growing Clinical Trials RenovoRx is actively advancing its Phase III TIGeR-PaC trial with enrollment surpassing 100 patients and a completion target in the first half of 2026, indicating strong momentum in clinical development and potential future demand for specialized oncology devices.

Expanding Market Adoption The company has tripled the number of actively requesting U.S. cancer centers for its FDA-cleared RenovoCath device, highlighting an increasing adoption trend that presents opportunities for partnerships and sales growth with oncology treatment providers.

Robust Financial Position With reported revenues between 25 and 50 million dollars and a recent oversubscribed 10 million dollar private placement, RenovoRx possesses the financial resources to scale commercial efforts and invest in expanding its customer base.

Recognition and Innovation Being named to Fast Company's list of the world's most innovative companies in 2026 underscores RenovoRx's cutting-edge position in biotechnology, which can be leveraged to attract healthcare institutions seeking innovative treatment solutions.

Market Expansion Opportunities The company’s success in gaining clinical and commercial momentum signals an opportunity to develop strategic partnerships, increase device placements, and expand outreach to oncology centers seeking effective targeted therapies.